WHAT IF ONE
GENE

Can change your entire world?

At AVROBIO, we aim to halt or reverse disease with a single dose of gene therapy. Our goal is simple and powerful: We aim to enable individuals with genetic disease to live longer — free from disease progression, free from painful and debilitating symptoms and free from the burden of chronic treatment regimens.

We're striving to deliver freedom for life

Illustration helix

OUR FOCUSA highly personalized therapy

Our investigational gene therapies start with the patient’s own stem cells. We are developing these treatments for several serious lysosomal disorders.

Learn about our areas of focus.

illustration plus sign

OUR APPROACHSolving the challenges of gene therapy

We've spent years developing a state-of-the-art platform to optimize gene therapies. We call it plato®.

Get to know plato®.

This block is broken or missing. You may be missing content or you might need to enable the original module.
This block is broken or missing. You may be missing content or you might need to enable the original module.

Our Views The latest on gene therapy from our expert team

Read our insights

Our News Our latest press releases

Sep 28 2020

AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 28, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-02, the

Read More

Sep 25 2020

AVROBIO to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming

Read More

Sep 04 2020

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000

Read More

See All

Join our team

Work with Us Join our team!

We are all about innovation. Collaboration. Dedication. And a quality we call “smart speed” — moving thoughtfully but with urgency to bring pioneering therapies to individuals living with genetic disease.

Explore careers at AVROBIO

By the numbers

3

countries where we’re conducting clinical trials 

4

disease indications in our pipeline 

30

years of foundational gene therapy science among our management team

ONE
GOAL:

to give individuals with genetic disease freedom for life

You are now leaving AVROBIO’s website.

The third party website to which you will be directed is not affiliated with AVROBIO, and AVROBIO assumes no responsibility for information or statements on third parties’ websites. Thank you for visiting avrobio.com.

Continue to URL Cancel